Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Glioblastoma 4Brain Neoplasms 4Neuroblastoma 3Recurrence 2Neoplasms 2Melanoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × TPI-287 × Clear all
NCT00867568 2024-08-06

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Milton S. Hershey Medical Center

Phase 1 Completed
18 enrolled 12 charts
CNS

Medulloblastoma, Neuroblastoma, Recurrence

NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡